Recombinant Vaccines against T. gondii: Comparison between Homologous and Heterologous Vaccination Protocols Using Two Viral Vectors Expressing SAG1

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Mendes, Érica Araújo ^a   Fonseca, Flavio G ^a,b   Casério, Bárbara M ^b   Colina, Janaína P ^a   Gazzinelli, Ricardo Tostes ^a,b,c   Caetano, Braulia C ^c  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MODIFIED VACCINIA VIRUS ANKARA; RECOMBINANT ADENOVIRUS VECTOR; SAG1 ANTIGEN; TOXOPLASMA GONDII VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; FEMALE; GENE EXPRESSION; HETEROLOGOUS VACCINATION; HOMOLOGOUS VACCINATION; IMMUNE RESPONSE; INFECTION CONTROL; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; TOXOPLASMOSIS; TRANSGENE; VACCINATION;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CYTOKINES; FEMALE; GENETIC VECTORS; IMMUNITY, CELLULAR; MICE; MICE, INBRED C57BL; PROTOZOAN PROTEINS; SPLEEN; T-LYMPHOCYTES; TOXOPLASMA; TRANSGENES; VACCINES, SYNTHETIC;

EID: 84877782578     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063201     Document Type: Article

References (87)

1. Dubey JP, Lindsay DS, Speer CA, (1998) Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. Clin Microbiol Rev 11: 267-299.
2. Dubey JP, (2004) Toxoplasmosis- a waterborne zoonosis. Vet Parasitol 126: 57-72.
3. Tenter AM, Heckeroth AR, Weiss LM (2000) Toxoplasma gondii: from animals to humans. Int J Parasitol. 1217-1258.
4. Tait ED, Hunter CA, (2009) Advances in understanding immunity to Toxoplasma gondii. Mem Inst Oswaldo Cruz 104: 201-210.
5. Melo MB, Jensen KD, Saeij JP, (2011) Toxoplasma gondii effectors are master regulators of the inflammatory response. Trends Parasitol 27: 487-495.
6. Sayles PC, Gibson GW, Johnson LL, (2000) B cells are essential for vaccination-induced resistance to virulent Toxoplasma gondii. Infect Immun 68: 1026-1033.
7. Johnson LL, Lanthier P, Hoffman J, Chen W, (2004) Vaccination protects B cell-deficient mice against an oral challenge with mildly virulent Toxoplasma gondii. Vaccine 22: 4054-4061.
8. McLeod R, Kieffer F, Sautter M, Hosten T, Pelloux H, (2009) Why prevent, diagnose and treat congenital toxoplasmosis? Mem Inst Oswaldo Cruz 104: 320-344.
9. Dabritz HA, Conrad PA, (2010) Cats and Toxoplasma: implications for public health. Zoonoses Public Health 57: 34-52.
10. Jenkins MC, (2001) Advances and prospects for subunit vaccines against protozoa of veterinary importance. Vet Parasitol 101: 291-310.
11. Schmidt DR, Hogh B, Andersen O, Hansen SH, Dalhoff K, et al. (2006) Treatment of infants with congenital toxoplasmosis: tolerability and plasma concentrations of sulfadiazine and pyrimethamine. Eur J Pediatr 165: 19-25.
12. Jongert E, Roberts CW, Gargano N, Forster-Wald E, Petersen E, (2009) Vaccines against Toxoplasma gondii: challenges and opportunities. Mem Inst Oswaldo Cruz 104: 252-266.
13. Dudek T, Knipe DM, (2006) Replication-defective viruses as vaccines and vaccine vectors. Virology 344: 230-239.
14. Yang TC, Millar JB, Grinshtein N, Bassett J, Finn J, et al. (2007) T-cell immunity generated by recombinant adenovirus vaccines. Expert Rev Vaccines 6: 347-356.
15. Hartman ZC, Appledorn DM, Amalfitano A, (2008) Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res 132: 1-14.
16. Huang X, Yang Y, (2009) Innate immune recognition of viruses and viral vectors. Hum Gene Ther 20: 293-301.
17. Lousberg EL, Diener KR, Brown MP, Hayball JD, (2011) Innate immune recognition of poxviral vaccine vectors. Expert Rev Vaccines 10: 1435-1449.
18. Rhee EG, Blattman JN, Kasturi SP, Kelley RP, Kaufman DR, et al. (2011) Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors. J Virol 85: 315-323.
19. Miyahira Y, Takashima Y, Kobayashi S, Matsumoto Y, Takeuchi T, et al. (2005) Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection. Infect Immun 73: 7356-7365.
20. Liu Y, Zhang S, Ma G, Zhang F, Hu R, (2008) Efficacy and safety of a live canine adenovirus-vectored rabies virus vaccine in swine. Vaccine 26: 5368-5372.
21. Barouch DH, (2010) Novel adenovirus vector-based vaccines for HIV-1. Curr Opin HIV AIDS 5: 386-390.
22. Sedegah M, Tamminga C, McGrath S, House B, Ganeshan H, et al. (2011) Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. PLoS One 6: e24586.
23. Miyata T, Harakuni T, Sugawa H, Sattabongkot J, Kato A, et al. (2011) Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine. Vaccine 29: 2720-2726.
24. Maroof A, Brown N, Smith B, Hodgkinson MR, Maxwell A, et al. (2012) Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis. J Infect Dis 205: 853-863.
25. Rocha CD, Caetano BC, Machado AV, Bruna-Romero O, (2004) Recombinant viruses as tools to induce protective cellular immunity against infectious diseases. Int Microbiol 7: 83-94.
26. Nolz JC, Harty JT, (2011) Strategies and implications for prime-boost vaccination to generate memory CD8 T cells. Adv Exp Med Biol 780: 69-83.
27. Bradley RR, Lynch DM, Iampietro MJ, Borducchi EN, Barouch DH, (2012) Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection. J Virol 86: 625-629.
28. Sumida SM, Truitt DM, Lemckert AA, Vogels R, Custers JH, et al. (2005) Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 174: 7179-7185.
29. Hill AV, Reyes-Sandoval A, O'Hara G, Ewer K, Lawrie A, et al. (2010) Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin 6: 78-83.
30. Lu S, (2009) Heterologous prime-boost vaccination. Curr Opin Immunol 21: 346-351.
31. Paris RM, Kim JH, Robb ML, Michael NL, (2010) Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. Expert Rev Vaccines 9: 1055-1069.
32. Esteban M, (2009) Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS. Hum Vaccin 5: 867-871.
33. Wyatt LS, Earl PL, Eller LA, Moss B, (2004) Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci U S A 101: 4590-4595.
34. Carroll MW, Moss B, (1997) Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238: 198-211.
35. Carroll MW, Moss B, (1997) Poxviruses as expression vectors. Curr Opin Biotechnol 8: 573-577.
36. Carroll MW, Overwijk WW, Chamberlain RS, Rosenberg SA, Moss B, et al. (1997) Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine 15: 387-394.
37. Schatzmayr HG, (2001) [Smallpox, an old foe]. Cad Saude Publica 17: 1525-1530.
38. Sutter G, Staib C, (2003) Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord 3: 263-271.
39. Boothroyd JC, Hehl A, Knoll LJ, Manger ID, (1998) The surface of Toxoplasma: more and less. Int J Parasitol 28: 3-9.
40. Mineo JR, Kasper LH, (1994) Attachment of Toxoplasma gondii to host cells involves major surface protein, SAG-1 (P30). Exp Parasitol 79: 11-20.
41. Araujo PR, Ferreira AW, (2010) High diagnostic efficiency of IgM-ELISA with the use of multiple antigen peptides (MAP1) from T. gondii ESA (SAG-1, GRA-1 and GRA-7), in acute toxoplasmosis. Rev Inst Med Trop Sao Paulo 52: 63-68.
42. Cong H, Mui EJ, Witola WH, Sidney J, Alexander J, et al. (2010) Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8+T cell epitope based, adjuvanted vaccine protective against Toxoplasma gondii. Immunome Res 6: 12.
43. Caetano BC, Bruna-Romero O, Fux B, Mendes EA, Penido ML, et al. (2006) Vaccination with replication-deficient recombinant adenoviruses encoding the main surface antigens of toxoplasma gondii induces immune response and protection against infection in mice. Hum Gene Ther 17: 415-426.
44. Mendes EA, Caetano BC, Penido ML, Bruna-Romero O, Gazzinelli RT, (2011) MyD88-dependent protective immunity elicited by adenovirus 5 expressing the surface antigen 1 from Toxoplasma gondii is mediated by CD8(+) T lymphocytes. Vaccine 29: 4476-4484.
45. Lunde MN, Jacobs L, (1983) Antigenic differences between endozoites and cystozoites of Toxoplasma gondii. J Parasitol 69: 806-808.
46. Sabin AB, (1941) Toxoplasmic encephalithes in children. J Am Med Assoc 116: 801-807.
47. Giraldo M, Cannizzaro H, Ferguson MA, Almeida IC, Gazzinelli RT, (2000) Fractionation of membrane components from tachyzoite forms of Toxoplasma gondii: differential recognition by immunoglobulin M (IgM) and IgG present in sera from patients with acute or chronic toxoplasmosis. J Clin Microbiol 38: 1453-1460.
48. Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, et al. (2004) Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci U S A 101: 6641-6646.
49. Bruna-Romero O, Lasarte JJ, Wilkinson G, Grace K, Clarke B, et al. (1997) Induction of cytotoxic T-cell response against hepatitis C virus structural antigens using a defective recombinant adenovirus. Hepatology 25: 470-477.
50. Kasper LH, Mineo JR, (1994) Attachment and invasion of host cells by Toxoplasma gondii. Parasitol Today 10: 184-188.
51. Tan TG, Mui E, Cong H, Witola WH, Montpetit A, et al. (2010) Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans. Vaccine 28: 3977-3989.
52. Angus CW, Klivington-Evans D, Dubey JP, Kovacs JA, (2000) Immunization with a DNA plasmid encoding the SAG1 (P30) protein of Toxoplasma gondii is immunogenic and protective in rodents. J Infect Dis 181: 317-324.
53. Bonenfant C, Dimier-Poisson I, Velge-Roussel F, Buzoni-Gatel D, Del Giudice G, et al. (2001) Intranasal immunization with SAG1 and nontoxic mutant heat-labile enterotoxins protects mice against Toxoplasma gondii. Infect Immun 69: 1605-1612.
54. Chen G, Chen H, Guo H, Zheng H, (2002) Protective effect of DNA-mediated immunization with a combination of SAG1 and IL-2 gene adjuvant against infection of Toxoplasma gondii in mice. Chin Med J (Engl) 115: 1448-1452.
55. Fang R, Feng H, Nie H, Wang L, Tu P, et al. (2010) Construction and immunogenicity of pseudotype baculovirus expressing Toxoplasma gondii SAG1 protein in BALB/c mice model. Vaccine 28: 1803-1807.
56. Liu KY, Zhang DB, Wei QK, Li J, Li GP, et al. (2006) Biological role of surface Toxoplasma gondii antigen in development of vaccine. World J Gastroenterol 12: 2363-2368.
57. Liu Q, Shang L, Jin H, Wei F, Zhu XQ, et al. (2010) The protective effect of a Toxoplasma gondii SAG1 plasmid DNA vaccine in mice is enhanced with IL-18. Res Vet Sci 89: 93-97.
58. Appledorn DM, Patial S, Godbehere S, Parameswaran N, Amalfitano A, (2009) TRIF, and TRIF-interacting TLRs differentially modulate several adenovirus vector-induced immune responses. J Innate Immun 1: 376-388.
59. Appledorn DM, Patial S, McBride A, Godbehere S, Van Rooijen N, et al. (2008) Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo. J Immunol 181: 2134-2144.
60. Muruve DA, Petrilli V, Zaiss AK, White LR, Clark SA, et al. (2008) The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 452: 103-107.
61. Pine SO, Kublin JG, Hammer SM, Borgerding J, Huang Y, et al. (2011) Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans. PLoS One 6: e18526.
62. Bradley RR, Maxfield LF, Lynch DM, Iampietro MJ, Borducchi EN, et al. (2012) Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions. J Virol 86: 1267-1272.
63. Pilankatta R, Chawla T, Khanna N, Swaminathan S, (2010) The prevalence of antibodies to adenovirus serotype 5 in an adult Indian population and implications for adenovirus vector vaccines. J Med Virol 82: 407-414.
64. Lasaro MO, Ertl HC, (2009) New insights on adenovirus as vaccine vectors. Mol Ther 17: 1333-1339.
65. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, et al. (1994) Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A 91: 4407-4411.
66. Yang Y, Wilson JM, (1995) Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo. J Immunol 155: 2564-2570.
67. Sumida SM, Truitt DM, Kishko MG, Arthur JC, Jackson SS, et al. (2004) Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol 78: 2666-2673.
68. Frahm N, DeCamp AC, Friedrich DP, Carter DK, Defawe OD, et al. (2012) Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest 122: 359-367.
69. Haut LH, Ratcliffe S, Pinto AR, Ertl H, (2011) Effect of preexisting immunity to adenovirus on transgene product-specific genital T cell responses on vaccination of mice with a homologous vector. J Infect Dis 203: 1073-1081.
70. Bangari DS, Mittal SK, (2006) Current strategies and future directions for eluding adenoviral vector immunity. Curr Gene Ther 6: 215-226.
71. Alexander J, Ward S, Mendy J, Manayani DJ, Farness P, et al. (2012) Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza h5 hemagglutinin. PLoS One 7: e31177.
72. Belousova N, Krendelchtchikova V, Curiel DT, Krasnykh V, (2002) Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. J Virol 76: 8621-8631.
73. Belousova N, Mikheeva G, Gelovani J, Krasnykh V, (2008) Modification of adenovirus capsid with a designed protein ligand yields a gene vector targeted to a major molecular marker of cancer. J Virol 82: 630-637.
74. Gilbert SC, Moorthy VS, Andrews L, Pathan AA, McConkey SJ, et al. (2006) Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine 24: 4554-4561.
75. Marthas ML, Van Rompay KK, Abbott Z, Earl P, Buonocore-Buzzelli L, et al. (2011) Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques. Vaccine 29: 3124-3137.
76. Kolibab K, Yang A, Derrick SC, Waldmann TA, Perera LP, et al. (2010) Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant. Clin Vaccine Immunol 17: 793-801.
77. Krupa M, Canamero M, Gomez CE, Najera JL, Gil J, et al. (2011) Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression. Vaccine 29: 1504-1513.
78. Reyes-Sandoval A, Rollier CS, Milicic A, Bauza K, Cottingham MG, et al. (2012) Mixed vector immunization with recombinant adenovirus and MVA can improve vaccine efficacy while decreasing antivector immunity. Mol Ther 20: 1633-1647.
79. Guiton R, Zagani R, Dimier-Poisson I, (2009) Major role for CD8 T cells in the protection against Toxoplasma gondii following dendritic cell vaccination. Parasite Immunol 31: 631-640.
80. Kang H, Liesenfeld O, Remington JS, Claflin J, Wang X, et al. (2003) TCR V beta 8+ T cells prevent development of toxoplasmic encephalitis in BALB/c mice genetically resistant to the disease. J Immunol 170: 4254-4259.
81. Wang X, Claflin J, Kang H, Suzuki Y, (2005) Importance of CD8(+)Vbeta8(+) T cells in IFN-gamma-mediated prevention of toxoplasmic encephalitis in genetically resistant BALB/c mice. J Interferon Cytokine Res 25: 338-344.
82. Vingert B, Benati D, Lambotte O, de Truchis P, Slama L, et al. (2012) HIV controllers maintain a population of highly efficient Th1 effector cells in contrast to patients treated in the long term. J Virol 86: 10661-10674.
83. Sanchez-Sampedro L, Gomez CE, Mejias-Perez E, Sorzano CO, Esteban M, (2012) High quality long-term CD4+ and CD8+ effector memory populations stimulated by DNA-LACK/MVA-LACK regimen in Leishmania major BALB/c model of infection. PLoS One 7: e38859.
84. Precopio ML, Betts MR, Parrino J, Price DA, Gostick E, et al. (2007) Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med 204: 1405-1416.
85. Reyes-Sandoval A, Berthoud T, Alder N, Siani L, Gilbert SC, et al. (2010) Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun 78: 145-153.
86. Suzuki Y, Wang X, Jortner BS, Payne L, Ni Y, et al. (2010) Removal of Toxoplasma gondii cysts from the brain by perforin-mediated activity of CD8+ T cells. Am J Pathol 176: 1607-1613.
87. Li H, Liu J, Carville A, Mansfield KG, Lynch D, et al. (2011) Durable mucosal simian immunodeficiency virus-specific effector memory T lymphocyte responses elicited by recombinant adenovirus vectors in rhesus monkeys. J Virol 85: 11007-11015.